Efficacy of treatment of small animals with triamcinolone-based medications for atopic dermatitis

Abstract

Among the diseases of small pets, skin diseases are one of the leading ones. Atopic dermatitis is a common skin condition in small pets, which, according to veterinarians’ estimates, affects 10-15% of dogs and 7-18% of cats. Depending on the allergens involved, clinical signs can be seasonal or non-seasonal, and the disease usually requires lifelong treatment. The purpose of this study was to investigate the therapeutic efficacy of treating atopy in dogs and cats with the use of triamcinolone-based veterinary medications (oral suspension). Standard clinical, haematological, biochemical, and immunological methods were used in the study. The increased content of total immunoglobulin E (Ig E) in the blood of experimental animals before treatment (Group I – 3.4 times, and Group II – 3.9 times compared to the control) indicates the presence of an allergic response in the body. It was found that the tested veterinary medications do not substantially affect the haematological parameters of dogs and cats when administered orally, and in therapeutic doses do not have a toxic effect on the functional state of the liver and kidneys. It was proved that on Day 4 of use of oral suspension No. 1 and No. 2 based on triamcinolone (1%) acetonide and a complex of B vitamins in a therapeutic dosage, an improvement in the general clinical condition of animals was recorded. On Day 8 of treatment, dogs and cats in experimental Groups I and II showed improvement in skin condition: a reduction in the lesion area, absence of redness, scratching, and exfoliation. The general clinical condition of the skin of the experimental animals stayed unchanged from Day 8 to Day 12. The developed oral suspensions have a pronounced anti-allergic effect and improve the skin condition of small pets (dogs and cats) with atopic dermatitis